Skip to Contents

Hanmi Pharmaceutical’s Combination Drug for Dyslipidemia Treatment, ‘Rosuzet’: Confirmed Non-inferiority Efficacy and Safety Compared to Monotherapy in ‘The Lancet’ & ‘European Heart Journal’

2023.03.22
share on Facebook share on Twitter copy url
란셋캡처본(사진).jpg

Hanmi Pharmaceutical’s Combination Drug for Dyslipidemia Treatment, ‘Rosuzet’: Confirmed Non-inferiority Efficacy and Safety Compared to Monotherapy in ‘The Lancet’ & ‘European Heart Journal’

PREV Hanmi Pharmaceutical to foster 'CMO Business' as its new growth engines at BIO Europe LIST NEXT Hanmi Pharmaceutical, announcing research data on 7 innovative anti-cancer drugs at AACR 2023